[Version 9,03/2022] corr. 11/2022

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Chronogest CR 20 mg controlled release vaginal medicated sponge for sheep

Chronogest CR (CY, FR, GR)
Chronogest 20 mg Liberacion Controlada (ES)
Chronogest CR 20 mg szabályozott hatóanyag-leadású hüvelyszivacs juhoknak A.U.V. (HU)
Chronogest CR, 20mg esponja vaginal de libertação controlada para ovinos (PT)
Chronogest CR 20mg controlled release vaginal sponge for sheep (XI)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each sponge contains:

Active substance:
17,9 mg flugestone equivalent to 20 mg flugestone acetate.

Excipients:

Qualitative composition of excipients and other constituents	**Quantitative composition if that information is essential for proper administration of the veterinary medicinal product**
Hydroxypropylcellulose	20 mg
Macrogol 4000	20 mg

White cylindrical polyester polyurethane medicated sponge equipped with string.

3. CLINICAL INFORMATION

3.1 Target species

Sheep (ewe and ewelamb).

3.2 Indications for use for each target species

In ewes and ewe lambs, in combination with PMSG (Pregnant Mare Serum Gonadotropin)
- Induction and synchronization of oestrus and ovulation (non cycling ewes during seasonal anoestrus and ewe lambs).
- Synchronization of oestrus and ovulation (cycling ewes and ewe-lambs).

3.3 Contraindications

None.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

- The repeated treatment with the product combined with PMSG may trigger the appearance of PMSG antibodies in some ewes. This in turn may affect the time of ovulation and result in reduced fertility when combined with fixed time artificial insemination at 55h following sponge removal.
- The repeated use of sponges within one year has not been studied.
- The use of a vaginal applicator designed for ewes or ewe lambs is recommended to correctly insert sponges and to avoid vaginal injuries.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Personal protective equipment consisting of single use gloves should be worn when handling the veterinary medicinal product.
The veterinary medicinal product should not be administered by pregnant women or women suspected to be pregnant.

Direct contact with the skin should be avoided.

If accidental contact with the skin occurs, wash the affected zone with soap and water. Wash hands after treatment and before meals.
Human exposure to this product can affect fertility.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Sheep (ewe and ewe lamb).

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Vaginal discharge[1]

[1] muco-purulent discharge may be observed at sponge removal. It is not associated with clinical signs and does not alter fertility.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder <or its local representative> or the national competent authority via the national reporting system. See also section "Contact details" of the package leaflet.
{<to be adjusted nationally>}

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

The use is not recommended during pregnancy.
Can be used during lactation.

3.8 Interaction with other medicinal products and other forms of interaction

The sponges should not be used in conjunction with alcohols, cresols, phenols, sheep dips or similar disinfectants.

3.9 Administration routes and dosage

The dose is one sponge per animal irrespective of body weight, breed, type (dairy or meat) and season.
The sponge is inserted intra-vaginally using an applicator.
Duration of sponge residence is 14 days. At the end of the administration period, the sponge is gently removed by pulling on its string.
To obtain an optimal synchronization of ovulation, an intra-muscular injection of PMSG (range 300-700 IU) is recommended (i.m.) at the time of sponge removal.
In case fixed time artificial insemination is applied, it is recommended to perform it 55 h after sponge removal.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

A five time overdose of flugestone acetate (100 mg/sponge) did not result in observable side effects.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Meat and offal: 2 days after withdrawal of sponges.
Milk: zero hours, including the treatment time.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QG03D

4.2 Pharmacodynamics

Flugestone acetate is a synthetic analogue of progesterone. It is approximately 20 fold more potent than progesterone and displays progestational activity but no anti-progestational, anti-androgenic or androgenic properties together with a low glucocorticoid activity.
Owing to its binding to the progesterone receptors, flugestone acetate acts by negative feed back on the hypothalamo-pituitary axis, suppressing pituitary release of gonadotropins and therefore terminal follicular growth and ovulation.

4.3 Pharmacokinetics

Flugestone acetate is readily absorbed during the 12-14 days period of intra-vaginal administration. T_{max} ranges between 8 and 24 h, whereas C_{max} varies between 1.4 and 3.7 ng/ml. Steady state is

reached quickly following onset of the treatment. Plasma cronolone concentrations are relatively constant throughout treatment. One day after removal of the Chronogest CR, flugestone acetate concentrations have dropped below the limit of quantification (LOQ = 0.04 ng/mL).

Flugestone acetate is metabolised into hydroxylated metabolites, which are excreted in faeces and urine.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

5.3 Special precautions for storage

Store below 25 °C.
Store in the original package.
Store in a dry place.
Once packaging is opened, any unused product should be discarded.

5.4 Nature and composition of immediate packaging

Not all pack sizes may be marketed.

Bags made of polyester/ aluminium/ polyethylene containing 10 sponges, 25 sponges or 50 sponges.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International B.V.

7. MARKETING AUTHORISATION NUMBER(S)

To be completed nationally

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: {DD month YYYY}

To be completed nationally

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{DD month YYYY}

To be completed nationally

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Polyester/ Aluminium/ Polyethylene Bags (10 sponges, 25 sponges and 50 sponges presentations)
[text appearing on label as no carton box will be used).

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Chronogest CR 20 mg controlled release vaginal medicated sponge for sheep
Chronogest CR (CY, FR, GR)
Chronogest 20 mg Liberacion Controlada (ES)
Chronogest CR 20 mg szabályozott hatóanyag-leadású hüvelyszivacs juhoknak A.U.V. (HU)
Chronogest CR, 20mg esponja vaginal de libertação controlada para ovinos (PT)
Chronogest CR 20mg controlled release vaginal sponge for sheep (XI)

2. STATEMENT OF ACTIVE SUBSTANCES

Flugestone acetate, 20 mg/sponge.
17,9 mg flugestone equivalent to 20 mg flugestone acetate.

3. PACKAGE SIZE

Polyethylene bag containing 10, 25 or 50 sponges.

4. TARGET SPECIES

Sheep (ewe and ewe lamb).

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Vaginal use.

7. WITHDRAWAL PERIODS

Withdrawal period:
Meat and offal: 2 days after withdrawal of sponges.
Milk: zero hours, including the treatment time.

8. EXPIRY DATE

To be completed nationally

9. SPECIAL STORAGE PRECAUTIONS

Store below 25 °C.

Store in the original package.
Store in a dry place.
Once packaging is opened, any unused product should be discarded.

10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

To be completed nationally

14. MARKETING AUTHORISATION NUMBERS

To be completed nationally

15. BATCH NUMBER

Lot {number}

The product should not be administered by pregnant women or women suspected to be pregnant.

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Chronogest CR 20 mg controlled release vaginal medicated sponge for sheep

Chronogest CR (CY, FR, GR)
Chronogest 20 mg Liberacion Controlada (ES)
Chronogest CR 20 mg szabályozott hatóanyag-leadású hüvelyszivacs juhoknak A.U.V. (HU)
Chronogest CR, 20mg esponja vaginal de libertação controlada para ovinos (PT)
Chronogest CR 20mg controlled release vaginal sponge for sheep (XI)

2. Composition

Each sponge contains:**Active substance(s)**
17,9 mg flugestone equivalent to 20 mg flugestone acetate.

List of excipients
Hydroxypropylcellulose, 20 mg
Macrogol 4000, 20 mg

White cylindrical polyester polyurethane medicated sponge equipped with string.

3. Target species

Sheep (ewe and ewe lamb).

4. Indications for use

In ewes and ewe lambs, in combination with PMSG (Pregnant Mare Serum Gonadotropin)
- Induction and synchronization of oestrus and ovulation (non cycling ewes during seasonal anoestrus and ewe lambs).
- Synchronization of oestrus and ovulation (cycling ewes and ewe-lambs).

5. Contraindications

None.

6. Special warnings

Special precautions for safe use in the target species:
- The repeated use of sponges within one year has not been studied.
- The use of a vaginal applicator designed for ewes or ewe lambs is recommended to correctly insert sponges and to avoid vaginal injuries.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Personal protective equipment consisting of single use gloves should be worn when handling the veterinary medicinal product.

The veterinary medicinal product should not be administered by pregnant women or women suspected to be pregnant.
Direct contact with the skin should be avoided. If accidental contact with the skin occurs, wash the affected zone with soap and water. Wash hands after treatment and before meals.
Human exposure to this product can affect fertility.

Pregnancy and lactation:
The use is not recommended during pregnancy.
Can be used during lactation.

Fertility:
- The repeated treatment with the product combined with PMSG may trigger the appearance of PMSG antibodies in some ewes. This in turn may affect the time of ovulation and result in reduced fertility when combined with fixed time artificial insemination at 55h following sponge removal.

Interaction with other medicinal products and other forms of interaction:
The sponges should not be used in conjunction with alcohols, cresols, phenols, sheep dips or similar disinfectants.

Overdose:

A five time overdose of flugestone acetate (100 mg/sponge) did not result in observable side effects.

Major incompatibilities:
None known.

7. Adverse events

Sheep (ewe and ewe lamb):

Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Vaginal discharge[1]

[1] muco-purulent discharge may be observed at sponge removal. It is not associated with clinical signs and does not alter fertility.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder <or the local representative of the marketing authorisation holder> using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

{<to be adjusted nationally>}

8. Dosage for each species, routes and method of administration

The dose is one sponge per animal independent of the body weight, breed, type and season.
For vaginal use using an applicator.

9. Advice on correct administration

The dose is one sponge per animal irrespective of body weight, breed, type (dairy or meat) and season.
The sponge is inserted intra-vaginally using an applicator.
Duration of sponge residence is 14 days. At the end of the administration period, the sponge is gently removed by pulling on its string.
To obtain an optimal synchronization of ovulation, an intra-muscular injection of PMSG (range 300-700 IU) is recommended (i.m.) at the time of sponge removal.
In case fixed time artificial insemination is applied, it is recommended to perform it 55 h after sponge removal.

10. Withdrawal periods

Meat and offal: 2 days after withdrawal of sponges.
Milk: zero hours, including the treatment time.

11. Special storage precautions

Keep out of the sight and reach of children.
Store below 25 °C.
Store in the original package.
Store in a dry place.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Once packaging is opened, any unused product should be discarded.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems applicable to the veterinary medicinal product concerned.
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

To be completed nationally

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

<{DD month YYYY}>
To be completed nationally

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder <and manufacturer responsible for batch release> <and contact details to report suspected adverse reactions>:
{< > to be adjusted nationally}

Manufacturer responsible for batch release:
Intervet Productions S.A.
Rue De Lyons
Igoville
27460
France

<Local representatives <and contact details to report suspected adverse reactions>:>
{< > to be adjusted nationally}

<For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.
{< > to be adjusted nationally}